5-Hydroxytryptamine Receptor 7 (5-HT7) Market

A government-set Medicare price for brexpiprazole is the first hard consequence of the Inflation Reduction Act for 5-HT7-active medicines: CMS named Rexulti among 15 drugs for its third negotiation cycle on 27 January 2026, after USD 1.08 billion of Medicare spending across 119,000 enrollees. The 5-Hydroxytryptamine Receptor 7 (5-HT7) market covers branded and generic medicines whose approved labels describe 5-HT7 receptor antagonism, plus selective 5-HT7 research ligands. Douglas Insights sizes it at USD 3.11 billion in 2025, rising to USD 4.06 billion in 2035, a revenue CAGR of 2.69%. The arithmetic: 1.04 million patient-years of therapy at an average net USD 2,996 per patient-year equals USD 3.11 billion. The study belongs to our pharmaceuticals coverage, and every figure follows the research methodology published on this site.

Which companies sell 5-HT7 receptor antagonist medicines, and how concentrated is supply?

Otsuka and Lundbeck together hold an estimated 71.6% share of 5-HT7 receptor market revenue in 2025, through brexpiprazole and vortioxetine. Douglas Insights puts the top-three concentration, adding Takeda, at about 78.4% of value. Generic lurasidone suppliers and two research-reagent houses make up the rest of the 5-HT7 field.

Lundbeck carries the deepest 5-HT7 franchise. Its full-year 2025 accounts show Brintellix and Trintellix (vortioxetine) revenue of DKK 4.55 billion, down 6% in Danish kroner, with Europe up 15% to DKK 2.01 billion and the United States down 19% to DKK 1.29 billion. The same accounts show Lundbeck’s Rexulti revenue up 19% to DKK 6.21 billion. The US label for vortioxetine records a 5-HT7 binding constant of 19 nM and lists the molecule as a 5-HT7 antagonist, which is why the Trintellix prescribing information anchors this scope.

Otsuka names Rexulti as a growth driver in its 2026 integrated report, and Lundbeck books its alliance share; the Rexulti label gives a 5-HT7 constant of 3.7 nM and three indications. Takeda co-commercialises vortioxetine in Japan with Lundbeck under a 2007 alliance, confirmed when the two companies announced Japanese approval on 20 September 2019.

Sumitomo Pharma owns the Latuda brand of lurasidone, the most 5-HT7-potent marketed molecule in the set. Generic entry broke that franchise: Lupin launched lurasidone tablets in five strengths on 21 February 2023, citing USD 4.2 billion of annual US Latuda sales, and Aurobindo followed within weeks. Bio-Techne, through Tocris, and Merck KGaA, through Sigma-Aldrich, both list SB-269970, the reference selective 5-HT7 antagonist used in receptor research.

Douglas Insights estimates these shares from disclosed product revenues and Medicare spending; remaining revenue sits with regional licensees of the same three molecules.

Which 5-HT7 receptor molecule makes the money, and which segment grows fastest?

Brexpiprazole makes the money, carrying 58.4% of 5-HT7 receptor market value, or USD 1.82 billion in 2025. Its label spans schizophrenia, adjunctive major depressive disorder and agitation associated with dementia due to Alzheimer’s disease. Selective 5-HT7 research ligands grow fastest, at 7.3% a year.

Brexpiprazole holds USD 1.82 billion because one tablet carries three US indications and the newest one, Alzheimer’s agitation, has no generic competitor. Vortioxetine accounts for USD 986.4 million; its European growth offsets a shrinking US base, so the segment barely moves at 0.4% a year. Lurasidone keeps USD 267.6 million, mostly generic volume at a fraction of the old brand price, and shrinks 4.6% a year as tender prices fall further.

Selective 5-HT7 research ligands are worth USD 40.5 million, the smallest slice. Tool compounds such as SB-269970 sell by the milligram to academic and pharmaceutical laboratories studying circadian rhythm, mood and cognition, and the segment’s 7.3% growth reflects rising receptor-pharmacology screening rather than patient demand. The receptor-research slice doubles to USD 81.9 million by 2035, still below 2.1% of the total.

By channel, retail pharmacy dispenses the bulk of brexpiprazole and vortioxetine; hospital pharmacy matters for acute schizophrenia admissions; research supply is the catalogue route for ligands.

Why is demand for 5-HT7 receptor antagonist therapy still rising?

Patient volume for 5-HT7 receptor drugs rises 3.10% a year in the base case, driven by brexpiprazole label expansion, European vortioxetine uptake, Japanese growth and cheaper generic lurasidone. Douglas Insights expects these four drivers to add 1.04 million patient-years in 2025 up to about 1.41 million in 2035.

Brexpiprazole’s breadth is the first engine, worth 1.45 points of the volume leg. The Rexulti label covers adults and adolescents aged 13 and over with schizophrenia, adjunctive treatment of major depressive disorder and agitation associated with dementia due to Alzheimer’s disease. Lundbeck’s own Rexulti revenue rose 19% in 2025 to DKK 6.21 billion, and Medicare alone counted 119,000 enrollees on the drug in the year to October 2025, according to the CMS selection fact sheet of 27 January 2026. Each new prescriber group adds patients without cannibalising an older indication.

European vortioxetine is the second engine, worth 0.62 points. Brintellix revenue in Europe rose 15% to DKK 2.01 billion in 2025 while the US line fell, a sign that European psychiatrists still move patients onto the 5-HT7 and 5-HT3 antagonist profile after first-line selective serotonin reuptake inhibitors (SSRIs) fail. Douglas Insights counts Europe as 21.4% of 5-HT7 receptor market value today.

Asia Pacific contributes 0.58 points. Vortioxetine reached Japan through the Takeda and Lundbeck co-commercialisation announced on 20 September 2019, and Douglas Insights models steady new starts there as the alliance matures. Douglas Insights models Asia Pacific patient-years rising faster than any other region, at 4.12% a year in value.

Cheap lurasidone is the fourth engine, worth 0.45 points. Generic lurasidone has been on US shelves since 21 February 2023, and lower prices widen access in Medicaid and uninsured schizophrenia care. Volume rises even as the molecule’s value falls, so the 5-HT7 patient pool keeps growing. Together the four drivers add 1.45 + 0.62 + 0.58 + 0.45 = 3.10 points.

Receptor research adds a small fifth push that sits inside the ligand segment rather than the patient count. Selective 5-HT7 tools such as SB-269970, with a 5-HT7A pKi of 8.9 against 7.2 for 5-HT5A and below 6.0 for nine other serotonin subtypes, let laboratories isolate the receptor in circadian, mood and pain models. Douglas Insights expects ligand revenue to grow 7.3% a year, from USD 40.5 million, as contract screening houses add 5-HT7 panels. None of that demand appears in patient-years, which is why the volume leg stays at 3.10%.

Which headwinds hold back 5-HT7 receptor drug revenue to 2035?

Three price headwinds remove 1.14 points a year from 5-HT7 receptor market pricing, turning a gross 0.74-point uplift into a net price leg of -0.40%. Medicare negotiation of brexpiprazole, continuing lurasidone generic erosion and US vortioxetine rebate pressure are the three, in that order of weight.

Medicare negotiation is the largest drag, at 0.55 points. CMS ranked Rexulti 12th among the 50 top negotiation-eligible drugs with USD 1,075,274,000 of Part B and Part D spending, and selected it on 27 January 2026 for prices that apply from 2028. A negotiated maximum fair price cuts the net price on the single biggest 5-HT7 receptor product in its biggest payer channel.

Lurasidone generics remove 0.38 points. Lupin’s launch release valued US Latuda sales at USD 4.2 billion before generic entry; Douglas Insights now puts the whole lurasidone segment at USD 267.6 million worldwide, an erosion of more than 90% in branded-equivalent value that keeps compressing tender prices.

US vortioxetine pressure takes 0.21 points. Trintellix US revenue fell 19% to DKK 1.29 billion in 2025, while CMS still ranked the drug 31st on its top-50 list with USD 392,499,000 of Medicare spending in the January 2026 fact sheet. A drug that high on the list remains a candidate for a later negotiation cycle, and rebate demands rise in step.

Where in the world is 5-HT7 receptor drug revenue concentrated?

North America leads the 5-HT7 receptor market with USD 1.92 billion in 2025, 61.7% of value, because brexpiprazole’s three US indications sit there. Asia Pacific grows fastest at 4.12% a year, and the Middle East and Africa is the wildcard at 1.35%.

North America reaches USD 2.41 billion by 2035 at 2.31% a year, the slowest of the large regions because Medicare negotiation lands there first. Europe holds USD 665.9 million and grows 2.86% a year to USD 882.8 million on vortioxetine and Rexulti alliance growth. Asia Pacific holds USD 382.7 million and climbs to USD 573.1 million as Japanese vortioxetine and Chinese lurasidone generics add patients.

Latin America holds USD 90.2 million and grows 3.54% a year to USD 127.7 million in our model, led by Brazil and Mexico private-pay prescriptions. The Middle East and Africa accounts for USD 52.9 million and only 1.35% annual growth; it is the wildcard because Gulf formularies can add a 5-HT7 receptor antidepressant in a single tender cycle and move the figure sharply.

How much do payers pay per patient-year for 5-HT7 receptor drugs?

The blended net price for 5-HT7 receptor drugs is USD 2,996 per patient-year in 2025, a Douglas Insights estimate that mixes high branded prices with near-commodity generic lurasidone. Medicare’s gross Rexulti spending works out at about USD 9,036 per enrollee before rebates.

Douglas Insights estimates the realised net bands as follows: branded brexpiprazole USD 6,100 to USD 7,400 per patient-year in the United States and USD 2,300 to USD 3,100 in Europe; branded vortioxetine USD 1,450 to USD 3,900 depending on country; generic lurasidone USD 250 to USD 600. The Medicare figure divides USD 1,075,274,000 of spending by 119,000 enrollees, so it reflects list price before manufacturer rebates and partial-year use.

Research ligands price by the milligram. Sigma-Aldrich shows SB-269970 pricing only behind contract login, and Tocris lists 1 mg, 5 mg and 10 mg reconstitution tables, so receptor-tool revenue tracks laboratory budgets rather than reimbursement. Douglas Insights expects the blended price to fall to about USD 2,878 per patient-year by 2035, a -0.40% annual leg.

Which rules and payer policies shape 5-HT7 receptor drug pricing?

The Inflation Reduction Act is the rule that matters most for 5-HT7 receptor drugs. It put USD 1.08 billion of Medicare brexpiprazole spending under negotiation from 27 January 2026, according to the CMS selected drug list. US label law, European health-technology assessment and Japanese biennial price revisions set the rest.

FDA prescribing information defines the scope of this study. Section 12.2 of the vortioxetine label states the 5-HT7 constant of 19 nM; the brexpiprazole label gives 3.7 nM; the Australian product information for lurasidone gives 0.495 nM. Those numbers are why this market counts three drugs that most formularies file under antidepressants or antipsychotics: each one carries 5-HT7 antagonism in its regulator-approved pharmacology.

Hatch-Waxman generic approval is the other policy force. Once the first lurasidone generics launched on 21 February 2023, brand value collapsed within two years. Brexpiprazole and vortioxetine face the same process later, and the timing of their generic entry is the largest single swing factor after 2030.

What could change the 2035 outlook for 5-HT7 receptor medicines?

The base case puts the 5-HT7 receptor market at USD 4.06 billion in 2035, with a slower case of USD 3.28 billion and a faster case of USD 4.79 billion. The spread comes from patient-year growth and from how hard Medicare negotiation and generics push price.

The slower case assumes an early brexpiprazole generic and deep negotiated cuts after the 27 January 2026 selection. The faster case assumes Alzheimer’s agitation prescribing broadens and a selective 5-HT7 drug reaches Phase 3. Volume is the lever: at 2.10% a year the 2035 total drops to USD 3.68 billion, at 4.10% it rises to USD 4.47 billion.

Our 2.69% base CAGR sits below the 3.61% to 10.60% range of published estimates. Those estimates size broader serotonin-antagonist classes or single molecules without netting out generic lurasidone, so a lower figure for a payer-pressured 5-HT7 receptor basket is expected.

How is the 5-HT7 receptor market defined, and what does it exclude?

5-Hydroxytryptamine is the chemical name for serotonin, and the 5-hydroxytryptamine receptor 7 is the seventh serotonin receptor family. The 5-HT7 receptor market comprises medicines whose regulator-approved labels list 5-HT7 antagonism, namely brexpiprazole, vortioxetine and lurasidone, plus selective 5-HT7 research ligands. It excludes triptans, 5-HT3 antiemetics and drugs with only weak 5-HT7 binding.

Revenue is counted at manufacturer net prices in USD, at 2025 exchange rates, across four channels and five regions. Patients are counted as patient-years of therapy, so a patient on drug for six months adds 0.5. Indications covered are schizophrenia, major depressive disorder and dementia-related agitation in Alzheimer’s disease; no selective 5-HT7 drug holds a marketing approval today, so the pipeline sits in scenarios, not in the 2025 base.

Douglas Exclusive: the 5-HT7 Affinity-Weighted Revenue Index

The 5-HT7 Affinity-Weighted Revenue Index is a Douglas Insights model built from 6 company filing lines and 8 regulator, label and catalogue records. The 14 inputs are 6 Lundbeck revenue lines, 3 CMS records, 3 label binding constants, 1 IQVIA-based Latuda sales figure quoted by Lupin and 1 Tocris catalogue pKi value. It weights each segment’s 2025 revenue by its 5-HT7 binding strength, scaled so that a 1 nM binder counts once.

The finding is stark. Lurasidone, with a 5-HT7 constant of 0.495 nM, holds only 8.6% of 5-HT7 receptor market revenue but 48.4% of the index, USD 540.6 million of affinity-weighted value. Brexpiprazole at 3.7 nM takes 44.0%, vortioxetine at 19 nM only 4.7%, and research ligands 2.9%. The index totals USD 1.12 billion against USD 3.11 billion of sales.

The read-across for buyers: the molecule that engages the receptor hardest is now the cheapest, while most revenue sits in drugs where 5-HT7 is a secondary target. A first selective 5-HT7 medicine would therefore compete on mechanism against a USD 250 to USD 600 generic, not against branded pricing.

How does the 5-HT7 receptor market compare with wider psychiatric drug spending?

The 5-HT7 receptor market is a USD 3.11 billion slice of psychiatric pharmacotherapy, smaller than the USD 4.2 billion that Latuda alone earned in the United States before generics. Sibling studies give the wider context for that comparison.

Our Pharmaceutical Drug Market report frames the total prescription pool these molecules compete in. The AI in Mental Health Market study tracks the digital tools that increasingly triage depression patients before a 5-HT7-active drug is prescribed, and the Agoraphobia Treatment Market report covers anxiety-disorder prescribing that sits next to these depression and psychosis drugs.

What receipts and methodology sit behind the 5-HT7 receptor model?

The 5-HT7 receptor model multiplies 1.04 million patient-years by USD 2,996 per patient-year to reach USD 3.11 billion for 2025. It counts 38 countries, uses 14 sourced inputs and 2 cross-checks, and projects volume and price legs separately to 2035.

Patient-years come from 2025 product revenue divided by country net prices: about 0.27 million for brexpiprazole, 0.38 million for vortioxetine and 0.39 million for lurasidone, with ligands converted at an equivalent revenue rate. The receipt: 1.0386 million patient-years times USD 2,996 equals USD 3.11 billion.

Cross-check one: US Latuda sales of USD 4.2 billion before generics against USD 267.6 million for lurasidone now implies 93.6% value erosion, matching the -4.6% segment trend. Cross-check two: Medicare’s gross USD 9,036 per Rexulti enrollee against our USD 6,100 to USD 7,400 net band implies rebates of 18.1% to 32.5%, a plausible range for a negotiated antipsychotic. Regions sum to the global total in both 2025 and 2035.

Sources

1. CMS Selected Drugs for Initial Price Applicability Year 2028 (2026)
2. CMS Top 50 Negotiation-Eligible Drugs IPAY 2028 (2026)
3. US FDA Trintellix prescribing information (2023)
4. US FDA Rexulti prescribing information (2024)
5. Lupin Lupin launches lurasidone hydrochloride tablets in the US (2023)
6. Takeda Takeda and Lundbeck announce MHLW approval of Trintellix in Japan (2019)